SRRA SRRA

Sierra Oncology Stock Price

54.99
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
54.99
Volume 0
Bid Price 54.99
Ask Price 45.10
News -
Day High

Low
14.91

52 Week Range

High
55.19

Day Low
Company Name Stock Ticker Symbol Market Type
Sierra Oncology Inc SRRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 54.99 19:00:00
Open Price Low Price High Price Close Price Prev Close
54.99 54.99
Trades Volume Avg Volume 52 Week Range
0 0 - 14.91 - 55.19
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 54.99 USD

Period:

Draw Mode:

Sierra Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.25B 22.75M 14.65M $ - $ - -7.12 -8.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 375.55k 2.10%

more financials information »

Sierra Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SRRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months54.7855.1954.6554.92397,2500.210.38%
1 Year23.2555.1914.9135.27802,94731.74136.52%
3 Years0.3755.190.3018.09369,22054.6214,762.16%
5 Years3.2055.190.209.08462,69051.791,618.44%

Sierra Oncology Description

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.